156 related articles for article (PubMed ID: 36045304)
1. Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
Adams AM; Carpenter EL; Clifton GT; Vreeland TJ; Chick RC; O'Shea AE; McCarthy PM; Kemp Bohan PM; Hickerson AT; Valdera FA; Tiwari A; Hale DF; Hyngstrom JR; Berger AC; Jakub JW; Sussman JJ; Shaheen MF; Yu X; Wagner TE; Faries MB; Peoples GE
Cancer Immunol Immunother; 2023 Mar; 72(3):697-705. PubMed ID: 36045304
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
Carpenter EL; Van Decar S; Adams AM; O'Shea AE; McCarthy P; Chick RC; Clifton GT; Vreeland T; Valdera FA; Tiwari A; Hale D; Kemp Bohan P; Hickerson A; Smolinsky T; Thomas K; Cindass J; Hyngstrom J; Berger AC; Jakub J; Sussman JJ; Shaheen MF; Yu X; Wagner TE; Faries M; Peoples GE
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536936
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
[TBL] [Abstract][Full Text] [Related]
4. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
Vreeland TJ; Clifton GT; Hale DF; Chick RC; Hickerson AT; Cindass JL; Adams AM; Bohan PMK; Andtbacka RHI; Berger AC; Jakub JW; Sussman JJ; Terando AM; Wagner T; Peoples GE; Faries MB
Ann Surg Oncol; 2021 Oct; 28(11):6126-6137. PubMed ID: 33641012
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
Adams AM; Chick RC; Vreeland TJ; Clifton GT; Hale DF; McCarthy PM; O'Shea AE; Bohan PMK; Hickerson AT; Park H; Sloan AJ; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Wagner T; Faries MB; Peoples GE
Melanoma Res; 2021 Aug; 31(4):378-388. PubMed ID: 34193804
[TBL] [Abstract][Full Text] [Related]
6. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.
Hardin MO; Vreeland TJ; Clifton GT; Hale DF; Herbert GS; Greene JM; Jackson DO; Berry JE; Nichols P; Yin S; Yu X; Wagner TE; Peoples GE
Immunotherapy; 2018 Apr; 10(5):373-382. PubMed ID: 29473470
[TBL] [Abstract][Full Text] [Related]
7. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
Herbert GS; Vreeland TJ; Clifton GT; Greene JM; Jackson DO; Hardin MO; Hale DF; Berry JS; Nichol P; Yin S; Yu X; Wagner TE; Peoples GE
Vaccine; 2018 May; 36(23):3247-3253. PubMed ID: 29724512
[TBL] [Abstract][Full Text] [Related]
8. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
10. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
[No Abstract] [Full Text] [Related]
11. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
12. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
13. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM; Schneble EJ; Jackson DO; Hale DF; Vreeland TJ; Flores M; Martin J; Herbert GS; Hardin MO; Yu X; Wagner TE; Peoples GE
Cancer Immunol Immunother; 2016 Apr; 65(4):383-92. PubMed ID: 26894495
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor.
Zhang Y; Liu X; Wang R; Liu S; Wang Y; Jing L; Louis MDJ; Cao R
Biomed Pharmacother; 2018 Jan; 97():784-792. PubMed ID: 29112931
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.
von Euw EM; Barrio MM; Furman D; Levy EM; Bianchini M; Peguillet I; Lantz O; Vellice A; Kohan A; Chacón M; Yee C; Wainstok R; Mordoh J
J Transl Med; 2008 Jan; 6():6. PubMed ID: 18221542
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
17. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
20. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
